Gen1E is a company headquartered in the United States.
Gen1E is a drug development company that uses an AI platform to screen for treatments for rare inflammatory diseases such as ARDS, ALS, and cystic fibrosis; it reports a pipeline of 21 compounds and has completed Phase I for a lead ARDS compound.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.